Combivir: Advanced Dual Therapy for Effective HIV Management
Combivir
| Product dosage: 150mg+300mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.87 | $86.00 (0%) | 🛒 Add to cart |
| 60 | $2.38 | $172.00 $143.00 (17%) | 🛒 Add to cart |
| 90 | $2.19 | $258.00 $197.00 (24%) | 🛒 Add to cart |
| 120 | $1.90 | $344.00 $228.00 (34%) | 🛒 Add to cart |
| 180 | $1.71 | $516.00 $308.00 (40%) | 🛒 Add to cart |
| 270 | $1.57 | $774.00 $423.00 (45%) | 🛒 Add to cart |
| 360 | $1.43
Best per pill | $1032.00 $513.00 (50%) | 🛒 Add to cart |
Combivir represents a cornerstone in antiretroviral therapy, combining two potent nucleoside reverse transcriptase inhibitors into a single, fixed-dose tablet. This formulation is specifically designed to streamline treatment regimens for individuals living with HIV-1 infection, enhancing adherence while maintaining therapeutic efficacy. By integrating lamivudine and zidovudine into one pill, Combivir reduces pill burden and supports consistent dosing, which is critical for suppressing viral load and improving long-term health outcomes. Its established role in combination therapy makes it a reliable option for both treatment-naïve and experienced patients under medical supervision.
Features
- Fixed-dose combination tablet containing 150 mg lamivudine and 300 mg zidovudine
- Oral administration; film-coated for ease of swallowing
- Requires no refrigeration; stable at room temperature
- Manufactured under stringent quality control standards
- Available in blister packs of 60 tablets
Benefits
- Simplifies dosing schedule, reducing the risk of missed doses and supporting treatment adherence
- Effectively suppresses HIV viral replication when used as part of a combination antiretroviral regimen
- Helps maintain or increase CD4 cell counts, supporting immune function
- May delay disease progression and reduce the incidence of opportunistic infections
- Well-established safety and efficacy profile backed by extensive clinical use
Common use
Combivir is indicated in combination with other antiretroviral agents for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adults and pediatric patients weighing at least 30 kg. It is commonly used as a foundational component in first-line treatment regimens and may also be utilized in certain switch strategies for virologically suppressed patients seeking regimen simplification. Healthcare providers determine its use based on individual patient factors, including treatment history, resistance profile, and comorbid conditions.
Dosage and direction
The recommended dosage for adults and adolescents (weighing at least 30 kg) is one tablet taken orally twice daily. Combivir may be taken with or without food. It is crucial to adhere strictly to the prescribed dosing schedule to maintain effective drug concentrations and minimize the risk of resistance development. Dosage adjustment may be necessary in patients with impaired renal function; consultation with a healthcare provider is essential in such cases. Do not crush, chew, or break the tablet.
Precautions
- Regular monitoring of hematological parameters is advised due to the risk of anemia, neutropenia, or leukopenia associated with zidovudine
- Lactic acidosis and severe hepatomegaly with steatosis have been reported; discontinue use if clinical or laboratory findings suggest these conditions
- Use with caution in patients with pre-existing liver disease or risk factors for liver disease
- May cause fat redistribution and metabolic abnormalities over time
- Not a cure for HIV infection; does not reduce the risk of transmitting HIV to others
Contraindications
Combivir is contraindicated in patients with known hypersensitivity to lamivudine, zidovudine, or any component of the formulation. It should not be administered to patients with significantly reduced renal clearance (CrCl <50 mL/min) unless dose adjustment is implemented. Concurrent use with stavudine is contraindicated due to antagonistic effects. Avoid use in patients with hepatic decompensation.
Possible side effect
Common adverse reactions may include headache, nausea, malaise, fatigue, and insomnia. More serious side effects can include:
- Hematological toxicity (anemia, neutropenia, thrombocytopenia)
- Lactic acidosis
- Hepatic steatosis
- Myopathy
- Peripheral neuropathy
- Pancreatitis (rare)
- Lipodystrophy
Drug interaction
Combivir may interact with:
- Other nucleoside analogues (e.g., stavudine—contraindicated)
- Drugs that inhibit glucuronidation (e.g., valproic acid, probenecid) may increase zidovudine levels
- Ribavirin and other drugs associated with lactic acidosis
- Nephrotoxic agents may affect renal clearance of lamivudine
- Consult a healthcare provider before starting any new medication
Missed dose
If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to make up for a missed one. Consistent adherence is vital to maintain viral suppression; consider using reminder tools or discussing adherence strategies with a healthcare provider if doses are frequently missed.
Overdose
Symptoms of overdose may include nausea, vomiting, lethargy, and hematological disturbances. There is no specific antidote; treatment should be supportive and symptomatic, including monitoring of hematological parameters. Hemodialysis may remove lamivudine but is less effective for zidovudine. Contact a poison control center or seek immediate medical attention if overdose is suspected.
Storage
Store at room temperature (15-30°C or 59-86°F) in a dry place. Keep in the original container to protect from moisture. Do not use if the blister pack is damaged or tablets appear altered. Keep out of reach of children and pets.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any changes to your medication regimen. Individual patient needs may vary.
Reviews
“After switching to Combivir, my daily pill count decreased significantly, making it easier to stay consistent with my treatment. Viral load has remained undetectable for over two years.” — Maria L., 42
“As an infectious disease specialist, I value Combivir for its reliability in dual NRTI backbones. It simplifies regimens without compromising efficacy, though monitoring for hematological effects remains important.” — Dr. A. Reynolds, MD